Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Primary Purpose
Overweight, Obese
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
LLLT
Lorcaserin
Sponsored by

About this trial
This is an interventional treatment trial for Overweight focused on measuring overweight, obese, central adiposity, Laser, lorcaserin, low level laser therapy, belviq
Eligibility Criteria
Inclusion Criteria:
- be 18-70 years of age;
- have a body weight of greater than 50 kg (110 pounds);
- have a BMI 27-39.9 kg/m2;
- be weight concerned;
- be motivated to reduce their central adiposity;
- be able to participate fully in all aspects of the study;
- have understood and signed study informed consent.
Exclusion Criteria:
- have used weight loss medications or participated in a weight loss program within the past 30 days;
- are currently taking supplements known to affect weight, such as garcinia cambrogia.
- have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);
- have an implanted device (including pacemaker or lap band) in the targeted area of LLLT;
- have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression);
- have used an investigational drug within 30 days of study enrollment;
- have a recent history (past 30 days) of alcohol or drug abuse or dependence;
- are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the medication phase and are unwilling to use a reliable form of contraception;
- have a history of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease;
- have current uncontrolled hypertension (systolic > 165 mm Hg or diastolic > 95 mm Hg) documented on 2 separate occasions;
- have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission;
- Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery, etc.;
- medical, physical, or other contraindications for body sculpting/weight loss;
- current use of medication(s) known to affect weight levels/cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent;
- concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These drugs can be used to treat depression and/or migraines but are contraindicated with lorcaserin;
- any medical condition known to affect weight levels and/or to cause bloating or swelling;
- diagnosis of, and/or taking medication for, irritable bowel syndrome;
- active infection, wound or other external trauma to the areas to be treated with the laser;
- known photosensitivity disorder;
- are allergic to lorcaserin;
- current active cancer or currently receiving treatment for cancer; or
- have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence;
Sites / Locations
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
LLLT
Lorcaserin
LLLT and Lorcaserin
Arm Description
Low Level Laser Therapy (LLLT) once a week for 12 weeks
locarserin monotherapy - 10 mg, twice daily for 12 weeks
LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
Outcomes
Primary Outcome Measures
Change in Waist Circumference
The change in waist circumference from baseline to 3 months
Change in Weight
The change in weight from baseline to 3 months
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02129608
Brief Title
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Official Title
A Feasibility Pilot Comparing a Non-invasive Low Level Laser Therapy (LLLT) With Lorcaserin to Reduce Central Adiposity in Overweight Individuals.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Currently in the United States about 97 million adults are considered obese, accounting for about 33% of the American adult population (compared to 22.9% in 1988). Obesity, defined as a body mass index of 30.0 or higher, is accountable for 44% of the diabetes, 23% of the ischemic heart disease and between 7% and 41% of certain cancers. The Erchonia® Zerona™ 2.0 Laser (which will be used in this study) has been approved by the FDA (K123237) as a non-invasive dermatological aesthetic treatment which can be used by individuals intending to reduce circumference of hips, waist, and thighs. Lorcaserin is a selective serotonin 2C (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on anorexigenic pro-opiomelanocortin neurons in the hypothalamus. Lorcaserin was approved by the FDA on June 2012 for weight management in people with a BMI of > 27 kg/m2 (overweight) when accompanied by a weigh-related condition such as type 2 diabetes or high blood pressure or in people with a BMI > 30 kg/m2 (obese). The purpose of this pilot study is to obtain preliminary data on: 1) effectiveness of the combination of LLLT and lorcaserin for reducing abdominal subcutaneous fat in overweight/obese individuals; 2) impact of LLLT on inflammatory biomarkers, blood sugar, and cholesterol.
Detailed Description
This study is being done to find out how effective Low Level Laser Therapy (LLLT - Erchonia® Zerona™ 2.0 Laser) is compared to Lorcaserin (Belviq®) in helping overweight people reduce their weight gain - especially in the central body region. Subjects will undergo 2 screening visits in which the investigators will take their medical and weight concern histories; and if found eligible, they will be randomized to one of three groups: 1) 12 weeks of LLLT, 2) 12 weeks of Lorcaserin, and 3) 12 weeks of a combination of both Lorcaserin and LLLT. Full study participation will last approximately 6 months and consists of 10 visits- 9 clinical and 1 phone call. During this study subjects will be provided with weight prevention counseling and be asked to complete 3 additional fasting blood draws. There will be one urine pregnancy test (for females only) at the beginning of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obese
Keywords
overweight, obese, central adiposity, Laser, lorcaserin, low level laser therapy, belviq
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LLLT
Arm Type
Active Comparator
Arm Description
Low Level Laser Therapy (LLLT) once a week for 12 weeks
Arm Title
Lorcaserin
Arm Type
Active Comparator
Arm Description
locarserin monotherapy - 10 mg, twice daily for 12 weeks
Arm Title
LLLT and Lorcaserin
Arm Type
Active Comparator
Arm Description
LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
Intervention Type
Device
Intervention Name(s)
LLLT
Other Intervention Name(s)
Low Level Laser, Erchonia® Zerona™ 2.0 Laser
Intervention Description
The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Lorcaserin
Other Intervention Name(s)
Belviq
Intervention Description
10 mg pills twice daily for 12 weeks.
Primary Outcome Measure Information:
Title
Change in Waist Circumference
Description
The change in waist circumference from baseline to 3 months
Time Frame
3 months
Title
Change in Weight
Description
The change in weight from baseline to 3 months
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
be 18-70 years of age;
have a body weight of greater than 50 kg (110 pounds);
have a BMI 27-39.9 kg/m2;
be weight concerned;
be motivated to reduce their central adiposity;
be able to participate fully in all aspects of the study;
have understood and signed study informed consent.
Exclusion Criteria:
have used weight loss medications or participated in a weight loss program within the past 30 days;
are currently taking supplements known to affect weight, such as garcinia cambrogia.
have had weight fluctuations of 20 pounds or more in the past 6 months (self-report);
have an implanted device (including pacemaker or lap band) in the targeted area of LLLT;
have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression);
have used an investigational drug within 30 days of study enrollment;
have a recent history (past 30 days) of alcohol or drug abuse or dependence;
are currently pregnant or lactating, or are of child-bearing potential or are likely to become pregnant during the medication phase and are unwilling to use a reliable form of contraception;
have a history of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease;
have current uncontrolled hypertension (systolic > 165 mm Hg or diastolic > 95 mm Hg) documented on 2 separate occasions;
have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission;
Prior surgical intervention for body sculpting/weight loss, such as liposuction, abdominoplasty, stomach stapling, lap band surgery, etc.;
medical, physical, or other contraindications for body sculpting/weight loss;
current use of medication(s) known to affect weight levels/cause bloating or swelling and for which abstinence during the course of study participation is not safe or medically prudent;
concurrently taking a serotonergic drug (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), triptans, bupropion, dextromethorphan, St. John's Wort). These drugs can be used to treat depression and/or migraines but are contraindicated with lorcaserin;
any medical condition known to affect weight levels and/or to cause bloating or swelling;
diagnosis of, and/or taking medication for, irritable bowel syndrome;
active infection, wound or other external trauma to the areas to be treated with the laser;
known photosensitivity disorder;
are allergic to lorcaserin;
current active cancer or currently receiving treatment for cancer; or
have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ivana T. Croghan, PhD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27708788
Citation
Croghan IT, Ebbert JO, Schroeder DR, Hurt RT, Hagstrom V, Clark MM. A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss. BMC Obes. 2016 Sep 29;3:42. doi: 10.1186/s40608-016-0122-4. eCollection 2016.
Results Reference
result
Links:
URL
http://bmcobes.biomedcentral.com/articles/10.1186/s40608-016-0122-4
Description
Related Info
Learn more about this trial
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
We'll reach out to this number within 24 hrs